News

Uptravi Delays Progression of PAH Associated with Lupus and Other Connective Tissue Diseases, Trial Shows

Uptravi (selexipag) delays the progression of pulmonary arterial hypertension in people with PAH that is associated with connective tissue diseases, including lupus, a Phase 3 clinical trial shows. Patients also tolerate Uptravi well, researchers said. PAH associated with connective tissue disease is also known as PAH-CTD, and PAH associated with lupus…

Rituxan Successfully Treated Severe Neuropsychiatric Lupus, Case Report Says

A 49-year-old woman with severe demyelinating syndrome systemic lupus erythematosus (DS-SLE), where lupus affects the white matter in the brain, was successfully treated with Genentech‘s Rituxan (rituximab), along with other medications. The case report, “Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: an alternative to…

Lupus Prevalence Much Higher in Hispanic, Asian Women in Manhattan

Lupus is more prevalent among Hispanic and Asian women in Manhattan, and those women develop significantly greater organ complications, particularly kidney disease, a study from the NYU School of Medicine shows. The research, “The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New…

Metabolic Syndrome Seen to Be Prevalent, and Possible Cause of Heart Disease, in Lupus Patients

People with systemic lupus erythematosus (SLE) are more prone to developing metabolic syndrome — a cluster of metabolic and cardiovascular risk factors that include hypertension, obesity, poor glucose tolerance, and high levels of cholesterol and triglycerides, like fat, in the blood — than others, new study reports, noting the syndrome as a likely cause of heart disease…